Australia appears to be gain access to potentially transformative medication for obesity: Retatrutide. The dual molecule – acting on both GLP-1 and GIP receptors – shows significant results in clinical trials, pointing to meaningful drops in BMI. While regulatory clearance hasn't occurred with Au